The effect of high-intensity exercise on cognitive function in healthy older adults

Not Applicable

Completed

• Conditions: Alzheimer's disease; Cognitive decline; Neurological - Alzheimer's disease; Neurological - Other neurological disorders

• Registration Number: ACTRN12617000643370
• Lead Sponsor: Murdoch University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2017-05-03
• Study Completion: 2019-09-25
• Last Update Posted: 4 April 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

Aged 60-80 years, cognitively healthy (i.e. no diagnosis of dementia), adequate visual and auditory acuity to complete neuropsychological testing, willingness to participate in entirety of study, willingness and ability to provide written informed consent, able to provide a letter from usual GP endorsing participants ability to partake in all aspects of the study.

Exclusion Criteria

1.A diagnosis of AD or another neurodegenerative disease, or a score of less than 26 on the Mini Mental State Examination.
2.Presence of clinical depression as measured by a score of 6 or greater on the Geriatric Depression Scale (GDS) Short Form.
3.Inability to undertake cycling-based exercise due to neuromuscular and/or musculo-skeletal limitations.
4.Inability to obtain medical clearance to participate in the exercise program.
5.Lifetime history of schizophrenia, shizoaffective disorder, or bipolar disorder
6.Subjects with untreated obstructive sleep apnoea
7.History of electroconvulsive therapy or serious head injury resulting in a prolonged period of unconsciousness.
8.History of alcohol abuse or dependence within 2 years of screening
9.Participants with a history of cancer (other than skin or in situ prostate cancer) within the previous 5 years
10.Any significant systemic illness or unstable medical condition that could lead to difficulty complying with the protocol including: history of myocardial infarction in the past year or unstable or severe cardiovascular disease including angina or Congestive Heart, chronic renal failure, chronic hepatic disease, severe pulmonary disease, epilepsy etc.
11.Insulin-requiring diabetes or uncontrolled diabetes mellitus
12.Uncontrolled hypertension (systolic BP greater than 170 or diastolic BP greater than 100)
13.Participants in whom magnetic resonance imaging (MRI) is contraindicated including, but not limited to, those with a pacemaker, presence of metallic fragments near the eyes or spinal cord, or cochlear implant (Dental fillings do not present a risk for MRI).

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
A composite cognitive score calculated from test scores from validated neuropsychological tests. The neuropsychological tests used to comprise the composite score include: The California Verbal Learning Test, Brief Visual Memory Test, Verbal fluency, Trails B and Digit Span.[Post-intervention (6 months)]

Secondary Outcome Measures

Name	Time	Method
Brain volume measured using volumetric magnetic resonance imaging[Post-intervention (6 months)];Brain connectivity measured using functional magnetic resonance imaging[Post-intervention (6 months)];Blood biomarkers (these will be defined based on the most current evidence of biomarkers linked to AD pathology)[Post-intervention (6 months)];A composite cognitive score calculated from test scores from validated neuropsychological tests. The neuropsychological tests used to comprise the composite score include: The California Verbal Learning Test, Brief Visual Memory Test, Verbal fluency, Trails B and Digit Span.[12 months post-intervention (18 months from baseline)]